|
| Genetic manipulation of the mammary gland and potential applications |
|
https://doi.org/10.18632/oncotarget.27044
Hiroaki Tagaya, Kentaro Semba, Kosuke Ishikawa
|
| 4253-4254 |
|
| Modified Simon’s minimax and optimal two-stage designs for single-arm phase II cancer clinical trials |
|
https://doi.org/10.18632/oncotarget.26981
Jongphil Kim, Michael J. Schell
|
| 4255-4261 |
|
| PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix |
|
https://doi.org/10.18632/oncotarget.27008
Minakshi Mann, Sachin Kumar, Shyam S. Chauhan, Neerja Bhatla, Sunesh Kumar, Sameer Bakhshi, Ritu Gupta, Ashok Sharma, Lalit Kumar
|
| 4262-4275 |
|
| AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting |
|
https://doi.org/10.18632/oncotarget.26945
Alvin Y. Liu, Adelle D. Kanan, Tomasz P. Radon, Siama Shah, Mark E. Weeks, Julie M. Foster, Jane K. Sosabowski, Laurent Dumartin, Tatjana Crnogorac-Jurcevic
|
| 4276-4289 |
|
| Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer |
|
https://doi.org/10.18632/oncotarget.27019
Parameet Kumar, Joyeeta Chakraborty, Gauthaman Sukumar, Clifton Dalgard, Raghunath Chatterjee, Roopa Biswas
|
| 4290-4306 |
|
| CEMIP upregulates BiP to promote breast cancer cell survival in hypoxia |
|
https://doi.org/10.18632/oncotarget.27036
Anna Banach, Ya-Ping Jiang, Eric Roth, Cem Kuscu, Jian Cao, Richard Z. Lin
|
| 4307-4320 |
|
| Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval |
|
https://doi.org/10.18632/oncotarget.27039
Eva Ciruelos, Emilio Alba, Rafael López, Anna Lluch, Miguel Martín, Isabel Arroyo, Beatriz Navarro, David Carcedo, Ramón Colomer, Joan Albanell
|
| 4321-4332 |
|
| The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications |
|
https://doi.org/10.18632/oncotarget.27016
Cecilia Söderberg Nauclér, Jürgen Geisler, Katja Vetvik
|
| 4333-4347 |
|
| Correction: Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB |
|
https://doi.org/10.18632/oncotarget.27046
Sang Eun Park, Hye Jin Yi, Nayoung Suh, Yun-Yong Park, Jae-Young Koh, Seong-Yun Jeong, Dong-Hyung Cho, Choung-Soo Kim, Jung Jin Hwang
|
| 4348-4349 |
|
| Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes |
|
https://doi.org/10.18632/oncotarget.27048
Garima Yagnik, Martin Rutkowski, Sumedh S. Shah, Manish K. Aghi
|
| 4350-4350 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
